- 17Volume 4, 2021Jul 20, Issue 14Jun 02, Issue 11May 19, Issue 10May 04, Issue 9Apr 20, Issue 8Apr 06, Issue 7Mar 23, Issue 6Mar 09, Issue 5Feb 23, Issue 4Feb 09, Issue 3Jan 26, Issue 2
- 16Volume 3, 2020Dec 15, Issue 25Dec 01, Issue 24Nov 17, Issue 23Oct 06, Issue 20Sep 08, Issue 18Aug 25, Issue 17Jul 14, Issue 14Jun 30, Issue 13Jun 16, Issue 12Jun 02, Issue 11May 19, Issue 10May 05, Issue 9Mar 10, Issue 5Feb 25, Issue 4Feb 04, Issue 3Jan 21, Issue 2Jan 07, Issue 01
- 15Volume 2, 2019Dec 17, Issue 22Nov 12, Issue 20Oct 28, Issue 19Oct 15, Issue 18Sep 03, Issue 15Aug 21, Issue 14Aug 05, Issue 13Jul 22, Issue 12Jul 08, Issue 11Jun 03, Issue 9May 13, Issue 8Apr 22, Issue 7Mar 11, Issue 4Feb 04, Issue 2Jan 21, Issue 1
- 14Volume 1, 2018Dec 21, Issue 12Dec 03, Issue 11Nov 19, Issue 10Nov 05, Issue 9Oct 22, Issue 8Oct 09, Issue 7Sep 24, Issue 6Sep 10, Issue 5Aug 15, Issue 4Jul 15, Issue 3Jul 01, Issue 1
Agenus on Twitter
Introducing MiNK Therapeutics! Visit @MiNK_iNKT and minktherapeutics.com to explore investor.agenusbio.com/news-releases/…
Agenus to Provide Corporate Update and Second Quarter 2021 Financial Report Conference Call on Monday, August 9, 2021, at 8:30 a.m. ET investor.agenusbio.com/news-releases/…
@SiweiYang @ODayMD A recording of the presentation is available and can be accessed at wsw.com/webcast/blair5…
PD-1 resistance is a big challenge for I-O therapy, which the predictive potential of Agenus' VISION platform could help overcome. Listen to @ODayMD discuss this & other aspects of PD-1 resistance at the William Blair Biotech Focus Conference: investor.agenusbio.com/events/event-d…
@ZeroToStockHero @ODayMD This presentation does not begin until 4:20pm ET today. Click here to watch: wsw.com/webcast/blair5…
TUNE IN today to hear Dr. Steven O'Day @ODayMD speak on the William Blair Biotech Focus Conference 2021 panel “Novel Mechanisms and Strategies for Addressing PD-(L)1 Refractory/Resistant Tumors” at 4:20pm ET. Click to listen: wsw.com/webcast/blair5…
Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021 Agenus' CMO Steven O'Day, MD @ODayMD will participate in a panel on July 14 from 4:20 - 5:20 p.m. ET Click for more information & to register: investor.agenusbio.com/news-releases/…
Is Fc enhancement required for optimal performance of anti-TIGIT molecules? Dr. @dhanschand spoke at the @sitcancer seminar "The TIGIT Pathway: A Deep Dive in Cancer Immunotherapy Targets" to address this question & discuss this emerging IO target #TIGIT sitcancer.org/events/event-d…
Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777 Phase 1 dosing for AGEN1777 is expected to begin during the third quarter of 2021. @bmsnews investor.agenusbio.com/news-releases/…
Agenus' latest newsletter now available: A Strategy for Innovation: Significant Strides in the Field of I-O Since its founding Agenus has used its deep knowledge of the immune system's biology to create therapies to optimally target cancer. Read more: agenusbio.com/newsletters/ag…
June is Cancer Immunotherapy Month! At the World Vaccine Congress last month, Agenus' CMO @ODayMD spoke about how #immunotherapy has changed the landscape of cancer treatment and continues to evolve to provide benefit to even more #cancerpatients. #CIM21 investor.agenusbio.com/events/event-d…
Hear Agenus' Head of Drug Discovery Dr. Dhan Chand speak at the SITC seminar "The TIGIT Pathway: A Deep Dive in Cancer Immunotherapy Targets" TODAY from 2-4pm ET! Click here to register and watch: sitcancer.org/events/event-d… @dhanschand @sitcancer #immunotherapy #TIGIT
Agenus' Head of Drug Discovery Dhan Chand, PhD @dhanschand will speak at a @sitcancer seminar on #TIGIT on June 29 at 2 - 4pm EST. Mark your calendars to join the discussion on this exciting #Immunotherapy target! Register here: sitcancer.org/education/deep… twitter.com/sitcancer/stat…
Join expert faculty on June 29 for SITC's TIGIT Pathway: A Deep Dive in #Cancer #Immunotherapy Targets, which will discuss the emerging immunotherapy target, #TIGIT, including the pathway biology and therapeutic interventions using this pathway. REGISTER: https://t.co/7tp46JqHrv pic.twitter.com/sCCgK3sDwz
— Society for Immunotherapy of Cancer (@sitcancer) June 8, 2021
Agenus Announces U.S. FDA Acceptance and Priority Review of Balstilimab Biologics License Application for the Treatment of Recurrent or Metastatic Cervical Cancer The FDA has set a target action date of December 16, 2021. investor.agenusbio.com/news-releases/…
$AGEN listed as one of biggest #ASCO21 risers in @evaluatevantage stock round-up. Agenus presented on differentiated activity of anti-PD-1 antibody balstilimab & new clinical data on AGEN2373, a CD137 agonist antibody evaluate.com/vantage/articl…
Agenus at #ASCO21 Agenus’ CMO @ODayMD offers his thoughts on Agenus' #AI VISION platform and AGEN2373 data presented @ASCO. Click to read more: investor.agenusbio.com/news-releases/…
Agenus’ Presentations at #ASCO21 Demonstrate Differentiated Activity of Balstilimab and Provide Clinical Update on AGEN2373 Bal demonstrates superior tumor killing potential in a VISION study. AGEN2373 shows no liver toxicity; combo trials are planned investor.agenusbio.com/news-releases/…
Agenus' collaboration with @bmsnews will allow us to accelerate the advancement of our differentiated pipeline while also giving us greater optionality as we pursue the best development strategy for each individual asset. investor.agenusbio.com/news-releases/…
Agenus newsletter now available: Setting the Stage for Innovation with Our Own PD-1 Having a PD-1 is critical to our I-O strategy. It provides commercial flexibility & opportunities to advance this agent for strategic combinations Click to read: agenusbio.com/agenusnews-vol…
Agenus to Participate in Fireside Chat at the @Jefferies 2021 Virtual Healthcare Conference Agenus' President and COO @jbuell01 will participate in a fireside chat on Friday, June 4, 2021 from 10:30am - 10:55am ET investor.agenusbio.com/news-releases/…